ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations-Reference-Cited by-同舟云学术

ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations

Published:2021-03-24 Issue:2 Volume:2 Page:280-284
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Hecker Judith S.¹,Wahida Adam¹²^ORCID,Hameister Erik³⁴,Filo Aneta³,Ruland Jürgen³,Bassermann Florian¹,Hildebrandt Martin³⁵,Verbeek Mareike¹,Poeck Hendrik¹⁶

Affiliation:

1. Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany

2. Torsten‐Haferlach‐Leukemia‐Diagnostics Foundation Munich Germany

3. Institute of Clinical Chemistry and Pathobiochemistry TUM School of Medicine Technical University of Munich Munich Germany

4. Department of Medical Oncology and Hematology University of Zurich and University Hospital Zurich Zurich Switzerland

5. Department of Transfusion Medicine, Cellular Therapy and Hemostaseology University Hospital, LMU Munich Munich Germany

6. Department of Internal Medicine III, Hematology and Internal Oncology University Hospital Regensburg Regensburg Germany

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.190

Reference11 articles.

1. Bortezomib, lenalidomide and low‐dose dexamethasone (VRD) versus lenalidomide and low‐dose dexamethasone (Ld) for newly‐diagnosed multiple myeloma‐ a randomized phase III study;Mookerjee A;Blood.,2017

2. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

3. Rituximab in the treatment of autoimmune haematological disorders

4. Rituximab therapy for autoimmune haematological diseases

5. Therapeutic Plasma Exchange (TPE, plasmapheresis) for Treatment of Refractory Autoimmune Hemolytic Anemia (AIHA)